Compare LSPD & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LSPD | CDNA |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2020 | 2007 |
| Metric | LSPD | CDNA |
|---|---|---|
| Price | $9.70 | $24.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | $13.33 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.4M | 674.8K |
| Earning Date | 05-21-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $15.43 | $16.01 |
| Revenue Next Year | $10.94 | $11.31 |
| P/E Ratio | ★ N/A | $473.20 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $7.83 | $10.96 |
| 52 Week High | $14.34 | $24.13 |
| Indicator | LSPD | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 65.75 |
| Support Level | $8.55 | $15.80 |
| Resistance Level | $9.89 | N/A |
| Average True Range (ATR) | 0.39 | 1.04 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 80.88 | 93.00 |
Lightspeed Commerce Inc provides an omni-channel commerce-enabling SaaS platform. Its software platform provides customers with the functionality it needs to engage with consumers, manage their operations, accept payments, and grow their businesses. The company sells its platform through a direct sales force in the United States, Canada, United Kingdom, Australia, and other countries. It derives a majority of its revenue from the United States.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.